- Although results from early studies are promising, FDA approval or randomized phase III data are necessary before immune checkpoint inhibitors should be offered to patients with urothelial carcinoma outside of a clinical trial.
- PD-L1 staining is not yet a clinically viable predictive biomarker. Hopefully correlative studies embedded in ongoing trials will yield improved biomarkers to optimize patient selection.
- Eligible patients should be encouraged to enroll in clinical trials whenever possible to gain access to
promising treatments and help advance the field.